EU/3/08/601

Table of contents

About

On 19 January 2009, orphan designation (EU/3/08/601) was granted by the European Commission to Immunomedics GmbH, Germany, for milatuzumab for the treatment of multiple myeloma.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in February 2020 on request of the Sponsor.

Key facts

Active substance
Milatuzumab
Disease / condition
Treatment of multiple myeloma
Date of first decision
19/01/2009
Outcome
Withdrawn
EU designation number
EU/3/08/601

Sponsor's contact details

Immunomedics GmbH
Paul-Ehrlich-Str. 22/D1
63322 Rödermark
Germany
Telephone: +49 61 51 66 715 66
E-mail: europe@immunomedics.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating